BRISBANE, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that the landmark 100,000th AlloMap result has been provided.
The increasing use of AlloMap contributes to this milestone. More than 90% of US heart transplant centers are now using the guideline-recommended AlloMap for heart transplant patient surveillance. "AlloMap has become a standard of care to monitor heart transplant patients for probability of rejection," said Mario Deng, MD, cardiologist and professor of medicine at UCLA. "For a transplant patient, understanding the health of their allograft is the top priority and drives many clinical decisions we make on immunotherapy and dose levels. The wide adoption of AlloMap and its longitudinal variation, AlloMap Variability Score, highlights the informative value of novel diagnostic solutions for this highly complex patient population."
Mitch Nelles, Chief Operations
Officer at CareDx stated, "This marks an impressive milestone for AlloMap. We at CareDx are focused on timely delivery of a non-invasive solution for heart transplant patients to replace or complement invasive biopsies. Convenient and secure access to the test results are readily available to the healthcare providers and patients through the CareDx web portal. The combination of these data with the CareDx-supported Outcomes of AlloMap Registry (OAR) provide rich content and clinical insights for the "Big Data" analytics project that has been presented at national meetings."
CareDx, a leader in transplant
diagnostics solutions, has a deep understanding of the continuing diagnostic needs for transplant patients. CareDx will build on the success of AlloMap later this year with the launch of AlloSure, an advanced diagnostic test for kidney transplant patients.
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and
AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including
risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Sasha King, Chief Commercial Officer
T: +1 415-287-2393
Source: CareDx, Inc.
News Provided by Acquire Media